“Regardless of Roe-related regulatory or recessionary reservations, one thing is clear: Women’s health is population health, and companies like Maven have a more important role than ever to play in helping to advance human health and health equity through technology,” Shakir told TechCrunch.

Ryder notes that the $90 million round is definitely not being put “aside for a rainy day,” saying that “on one hand, we’re having more rigor in our budgeting and spending process like every company, but the new capital we’re investing in growth.”

Maven declined to share what new products are in the works, but Ryder did hint that they are building for the market demand for a better fertility and maternity bundle of benefits; “not only on the reimbursement side but also the clinical outcomes.” Maven is also working to support the Medicaid side of its business and is continuing to invest in health equity that “attacks … social determinant issues.”

Maven launched its first Medicaid population this year. For example, Maven launched with Arkansas Blue Cross Blue Shield this year and it is able to be offered as a free benefit to families who are enrolled in the plan.

Scale has brought the ability to spin up programs with fast impact. For example, within six weeks of launching a menopause program, over 1.2 million lives were covered across 150 employers. Additionally, Maven’s network of providers offer an average 5,100+ appointment slots every week. All factors that help play into the reason that the startup has a 96% client retention rate.

The challenge ahead of Maven, similar to any digital health clinic looking to have the biggest impact, is its ability to serve the most complex medical issues for high-risk, diverse patients.

In this case, let’s see how a new round at a higher valuation helps Maven do exactly what they say the industry wants.

Maven, now valued at $1.35 billion, is answering a countrywide demand: More fertility benefits by Natasha Mascarenhas originally published on TechCrunch